ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Takeda chief confronts growing pains -- and lack of growth -- without old ally

Christophe Weber needs some successes in his hunt for new-drug candidates

 (placeholder image)
Christophe Weber became president of Japanese drugmaker Takeda in June 2014.   © Reuters

OSAKA -- Takeda Pharmaceutical President Christophe Weber is under increasing pressure to prove that his rapidly globalizing Japanese company can return to earnings growth, a task the French-born CEO will have to face without the chairman who supported his rise.

Yasuchika Hasegawa retired as chairman at the close of Wednesday's shareholders meeting but will stick around with the title of corporate counselor. Stockholders angry over the drugmaker's lackluster earnings performance on his watch tried to abolish the new post, making for a tense moment at the meeting in Osaka.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more